Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TEMPO-3

- PMLiVE

Mission Therapeutics advances Parkinson’s disease candidate

The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

- PMLiVE

PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

The US-based company develops light-based therapies for neurodegenerative conditions

- PMLiVE

AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

- PMLiVE

AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon

Approximately 153,000 people in the UK are currently living with the neurodegenerative disorder

- PMLiVE

Study reveals single copy of protective genetic variant delays early Alzheimer’s onset

Approximately 900,000 people in the UK are affected by dementia and Alzheimer’s is the most common form

- PMLiVE

Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

The neurodegenerative condition currently affects nearly ten million people worldwide

- PMLiVE

Cerevel Therapeutics shares positive phase 3 results for tavapadon in Parkinson’s disease

The progressive neurodegenerative disease affects seven million people worldwide

- PMLiVE

Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease

According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019

- PMLiVE

Study reveals early menopause and higher CVD risk could be linked to cognitive decline

Approximately 733,040 people in Canada are estimated to be living with dementia

- PMLiVE

Two UK clinical trials launched to identify blood tests for dementia diagnosis

The neurodegenerative condition affects more than 944,000 people in the UK

- PMLiVE

NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy

The progressive neurodegenerative disease affects around ten million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links